Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial

Children's Oncology Group

Status: Completed

Conditions: Leukemia

Treatments: Genetic: microarray analysis; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Other: laboratory biomarker analysis; Genetic: gene mapping

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01507441

NCI-2012-00108 (Registry Identifier)

AAML12B4 (Other Identifier)

COG-AAML12B4 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.

Full description

OBJECTIVES:

• To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in patients with Down syndrome through whole-genome sequencing.

OUTLINE: This is a multicenter study.

Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene mutation, and microarray analysis.

Enrollment: 10 estimated patients

Sex: All

Ages: Under 3 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)

• Clinical samples from patients enrolled on the Children's Oncology Group (COG) AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell Bank

  • Diagnostic blast samples and matched remission samples

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified